GenScript ProBio--- A global multimodality CDMO, offers end-to-end CDMO services from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes in CGT and biologics, aiming to accelerate drug development for customers. The company announces the appointment of Dr. Li Chen, as the Chief Executive Officer of GenScript ProBio. She will report to Dr. Patrick Liu, Chairman of GenScript ProBio.
Dr. Li Chen has extensive experience in strategic business planning, operational excellence, and fostering robust businesses in various biotechnology fields. She previously served as Vice President/General Manager of Biologics Business Unit at West Pharmaceutical Services in the United States. In this role, she led the development and implementation of business expansion strategies across multiple areas, successfully achieving rapid growth of the company's business in the global market in alignment with overall strategic priorities. Dr. Li Chen's industrial experience began at Sigma-Aldrich, and she successively held significant leadership positions at Millipore, Merck, and other companies. After that, she spent a decade at Thermo Fisher Scientific, holding various key roles such as Vice President of China BID Business, Vice President of Asia-Pacific Business etc. Her high sensitivity to emerging technologies and market opportunities facilitated the successful transformation of the company's business, opening new growth paths and maintaining a leading position in the highly competitive industry.
Dr. Patrick Liu, Chairman of GenScript ProBio, stated, "GenScript ProBio is currently at a pivotal stage of development, and we are thrilled to welcome Dr. Li Chen at this crucial juncture. With her solid professional background, extensive managerial experience, and outstanding leadership capabilities, we anticipate that GenScript ProBio will enter a new phase of development under her guidance, we aim to enhance operational capabilities, expand our global presence, and provide more efficient and innovative services to clients worldwide."
Dr. Li Chen, Chief Executive Officer of GenScript ProBio, confidently expressed, "I am honored to have the opportunity to lead GenScript ProBio to its next milestones. In just few years, GenScript ProBio has built an impressive global presence and served customers all around the world. With more than 70 IND approvals globally, including United States, European Union, and Asia Pacific, GenScript ProBio has already established itself as a highly reliable CDMO. I am looking forward to collaborating with all the great minds of this company and leveraging my business acumen and experience in global strategic operations, to bring GenScript ProBio to the top rank global multi-modality CDMO.”